iFlash-2019-nCoV NAb (Neutralization Antibody) assay is a chemiluminescence immunoassay (CLIA) for the qualitative determination of 2019-nCoV Neutralization Antibodies in human serum or plasma. This assay can simulate the in vivo binding of SARS-CoV-2 RBD to ACE2-receptor in human host cells after SARS-CoV-2 infection or vaccination.
Clinical Benefits:
Evaluate COVID-19 vaccines development and efficacy
Monitor the NAb titers in COVID-19 patients and vaccinated individuals.
Analyze herd immunity status to guide policymakers.
Monitoring during convalescent plasma therapy or other antibody-related treatments.